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Abstract. Polycystic kidney diseases (PKDs) repre-
sent a large group of progressive renal disorders
characterized by the development of renal cysts
leading to end-stage renal disease. Enormous strides
have been made in understanding the pathogenesis of
PKDs and the development of new therapies. Studies
of autosomal dominant and recessive polycystic
kidney diseases converge on molecular mechanisms
of cystogenesis, including ciliary abnormalities and
intracellularcalciumdysregulation,ultimatelyleading
to increased proliferation, apoptosis and dedifferen-
tiation. Here we review the pathobiology of PKD,
highlighting recent progress in elucidating common
molecular pathways of cystogenesis. We discuss avail-
able models and challenges for therapeutic discovery
as well as summarize the results from preclinical
experimental treatments targeting key disease-specif-
ic pathways.
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Introduction
Polycystic kidney diseases (PKDs) are a large family
of disorders characterized by the formation and
growth of renal cysts often leading to end-stage renal
disease (ESRD). The most common inherited PKDs
can be transmitted as autosomal dominant or autoso-
mal recessive traits. Autosomal dominant polycystic
kidney disease (ADPKD) occurs with an incidence of
1:1000 and is characterized by the development of
fluid-filled cysts in the kidneys, liver, pancreas and
otherorgans,accountingforupto10%ofESRDcases
[1]. ADPKD is a systemic disorder with cardiovascu-
lar manifestations including cardiac valve abnormal-
ities, cardiac hypertrophy and intracranial aneurisms.
Intestinal diverticuli and abdominal wall hernia are
also common. Complications include hypertension,
abdominal pain, hematuria and urinary tract infec-
tions [2, 3]. The disease manifests in adulthood, with
~50% of patients developing renal failure by age 60
[4, 5].
Autosomal recessive polycystic kidney disease
(ARPKD) is a less frequent childhood disease with
an incidence of 1:20 000. ARPKD is characterized by
cystic kidneys and congenital hepatic fibrosis with a
high level of mortality in affected newborns. Most
cases manifest in utero or at birth with renal enlarge-
ment and biliary dysgenesis. A smaller number of
patients display later onset of disease with portal
hypertension or cholangitis [6]. There are several
other less common inherited recessive cystic diseases
including nephronophthisis (NPHP), Bardet-Biedl
syndrome (BBS), Joubert syndrome (JBTS) and
Meckel-Gruber syndrome (MKS) that will not be
discussed here and are described in other excellent * Corresponding author.
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Cellular and Molecular Life Sciencesreports[7–10].Thisreviewwillmainlyfocusonrecent
advances in understanding the molecular pathogene-
sis of PKDs and development of novel therapeutic
options.
Molecular genetics of PKDs
ADPKD. ADPKD is genetically and phenotypically
heterogeneous. Approximately 85% of all ADPKD
cases are caused by mutations in the PKD1 gene,
encoding polycystin-1, which maps to human chro-
mosome 16p13.3 [11–14]. The remaining 15% can be
attributed to the PKD2 gene, encoding polycystin-2,
which maps to 4q21 [15, 16]. Clinical presentations of
the PKD1 and PKD2 mutations are very similar,
although the disease phenotype in the latter is
significantly milder. Typically, individuals with
PKD2 display later mean age at diagnosis, hyper-
tensionandESRD[17,18].Heterogeneityisalsoseen
within families in age of onset, rate of cystic disease
progression and extrarenal manifestations, suggesting
the role of genetic and environmental factors [19].
The PKD1 genomic region of 53 kb is organized into
46 exons encoding a ~14 kb mRNA. Sequences
related to the PKD1 locus are duplicated several
times proximally on chromosome 16 [20]. The PKD1
genomic region contains a number of unusual struc-
turalfeatures,includinghighGCcontentandmultiple
simple repeats. Most interesting is the 2.5-kb polypyr-
imidine tract located within intron 21 [21]. Such
lengthy polypyrimidine elements may interfere with
replication,transcriptionorRNAprocessing.Because
of the complex structure of the PKD1 gene, compre-
hensive mutation screening is difficult. Approximate-
ly 270 different PKD1 mutations have been described
[19]. Most mutations are predicted to produce trun-
cated protein and are unique to a single family,
although missense mutations have also been identi-
fied.
The PKD2 gene has 15 exons encoding ~5 kb mRNA
[16]. Nearly 70 different mutations have been descri-
bed [19]. While genotype/phenotype correlations in
thePKD1genesuggestthatmutationsinthe5’portion
of the gene are associated with a more severe
phenotype, no obvious correlations have been found
in the PKD2 gene [22].
The combination of the unique unstable structural
elements in the PKD1 gene with intrafamilial hetero-
geneity and the focal nature of cyst formation has led
to the ”two-hit hypothesis” for cyst formation, which
suggests that cysts form in cells with an inherited
mutation in one allele and a somatic mutation occur-
ring in the other allele. This hypothesis received
experimental support through identification of so-
matic mutations in a subset of kidney cysts [23, 24]. A
similar mechanism was also found to play a role in
PKD2 renal and hepatic cystogenesis [25]. Further
studies suggest, however, that other mechanisms may
be involved. Cystogenesis in humans and mice occurs
in trans-heterozygotes with PKD1 and PKD2 muta-
tions[26,27].Inaddition,loweringofPkd1expression
is sufficient to cause PKD in mice [28]. It is possible
that reduced expression of the normal PKD1 allele
below a critical level due to genetic or environmental
factors may lead to cyst formation in the kidneys of
ADPKD patients [28]. On the other hand, over-
expression of polycystin-1 in transgenic animals also
results in cyst formation [29, 30]. These data suggest
that abnormal levels of polycystin-1 expression can
trigger pathogenic mechanisms leading to cyst forma-
tion.
ARPKD.Geneticdatahaveshownthatmutationsina
single gene, PKHD1, located on chromosome 6p21
(encoding fibrocystin/polyductin) cause ARPKD [31,
32]. The PKHD1 gene spans a region of ~500 kb,
consists of 67 exons and encodes a large ~16 kb
mRNA. Over 300 disease-causing mutations have
been identified [33, 34]. Genotype/phenotype corre-
lations show that individuals with two truncating
mutationsdieintheperinatalperiod,whileoneortwo
missense changes are associated with milder disease
[33]. This finding was further supported by a study of
neonatal survivors in which no two truncating muta-
tions were identified, suggesting that missense muta-
tions are required for survival of newborns [35]. The
majority of PKHD1 mutations are unique to a single
family, with no obvious hot spots identified [35].
PKD proteins
Polycystin-1. Polycystin-1, the product of the PKD1
gene, is a large transmembrane protein with an
estimated molecular weight of ~500 kD (Fig. 1) [12,
13]. The large extracellular N-terminal region con-
tains several specific motifs including leucine-rich
repeats(LRRs),C-typelectindomain,LDL-Aregion,
multiple Ig-like domains (or PKD domains), REJ
domain and GPS domain. It has 11 transmembrane
domains, with a PLAT domain located in the first
cytoplasmicloopandasmallcytoplasmictailwithaG-
protein-binding motif and coiled-coil region (Fig. 1).
The 16 Ig-like domains are segmented such that the
firstIg-likedomainislocalizedbetweentheLRRsand
the C-type lectin domain, while the remaining 15 Ig-
like domains are clustered together between LDL-A
and REJ domains. This Ig-like domain cluster forms
strong homophilic interactions that are important for
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multifunctional protein with important roles in cell-
cell/matrix adhesion and ciliary functions [10, 38].
Polycystin-1 undergoes partial cleavage at the GPS
domain such that N-terminal and C-terminal poly-
peptides remain non-covalently linked [39, 40]. It is
subsequentlycleavedatthesecondsite,whichreleases
its C-terminal tail [41]. The cytoplasmic tail of
polycystin-1 enters the nucleus and regulates cell
signaling events. This signaling function of polycys-
tin-1 is regulated by polycystin-2 and may possibly be
initiated by mechanical stimuli [41].
Polycystin-2.Polycystin-2isaproteinof~110 kDwith
six transmembrane domains and cytoplasmic N- and
C-terminal domains (Fig. 1) [16]. Polycystin-2 (or
TRPP2) is thought to be a new member of the
transient receptor potential (TRP) family of ion
channels. It was shown to be a cation channel with
someselectivityforCa
2+[42]andfunctionsinmultiple
subcellular locations including plasma membrane [43,
44], endoplasmic reticulum [45] and the primary cilia
[46].
Polycystin-1and-2canfunctiontogetherasacomplex
as well as independently in a variety of subcellular
compartments. Direct interaction between the cyto-
plasmic tails of the polycystins has been shown using
yeast two-hybrid assay [47, 48].
Fibrocystin/polyductin.Fibrocystinisalargereceptor-
like membrane-associated protein of ~450 kD with a
single transmembrane domain, large extracellular N-
terminalregionandsmallcytoplasmicC-terminaltail.
Its extracellular portion consists of several TIG
domains (immunoglobulin-like) and a short cytoplas-
mic C-terminus with putative phosphorylation sites
(Fig. 1) [49, 50]. Based on similarities with other TIG-
containing proteins such as the hepatocyte growth
factor receptor and the plexins, fibrocystin was
suggested to function as a receptor or a ligand, since
secreted forms may be generated from alternatively
spliced transcripts [49]. Fibrocystin is expressed in
cortical and medullary collecting ducts of the kidney
as well as biliary and pancreatic ducts in a pattern
consistent with the histologic features seen in
ARPKD [50].
Similar to polycystins, fibrocystin is expressed in
multiple subcellular locations including the basolat-
eralmembrane,cytoplasmandcilia.Ithasbeenshown
that fibrocystin can undergo Notch-like processing
withreleaseoftheectodomainfromprimarycilia[51].
An independent study also showed cleavage of the
ectodomain of fibrocystin as well as generation of a
cytoplasmic fragment that translocates to the nucleus
[52]. Such proteolytic cleavage can be elicited by
stimulation of intracellular Ca
2+ release or protein
kinase C activation. Fibrocystin may form a complex
with polycystin-2 to regulate calcium responses in
kidneyepithelia,butitsexactroleinnormalandcystic
epithelia is not known [53].
Cellular and molecular pathogenesis of PKDs
Proliferation, apoptosis and fluid secretion in cysts.
The formation and growth of cysts in PKD is
accompaniedbyincreasedproliferationandapoptosis
of cyst-lining epithelia, loss of epithelial polarity and
Figure 1. The structure of poly-
cystin-1, polycystin-2 and fibro-
cystin (LRR, leucine-rich re-
peats; WSC, cell wall integrity
andstressresponsecomponent1;
PKD (Ig-like), Ig-like domains;
LDL, low density lipoprotein
domain; REJ, receptor for egg
jelly;GPS,proteolyticGprotein-
coupledreceptorproteolyticsite;
PLAT,lipoxygenasedomain;EF,
EF hand domain; TIG, immuno-
globulin-like domains; TMEM2,
homology with TMEM2 pro-
tein). Polycystin-1 and fibrocys-
tin undergo cleavage at sites
shown by the arrows.
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actionsandtransformationoftheabsorptiveepithelial
phenotype to a secretory phenotype [54–56]. Epider-
mal growth factor (EGF), transforming growth factor
(TGF) alpha and EGF receptor (EGFR) play impor-
tant roles in promoting cystic epithelial proliferation.
In human PKDs and several animal models, EGFR is
overexpressed and mislocalized to the apical mem-
branesofcysticepithelialcells[57].Overexpressionof
TGF alpha in transgenic animals leads to renal cyst
formation [58]. Apoptosis is also essential for cysto-
genesis: deletion of the anti-apoptotic Bcl-2 and
AP-2b genes and overexpression of the pro-apoptotic
genec-mycinmiceresultsinrenalcystformation[59].
Cystic fluid is derived from glomerular filtrate in the
early stages of ADPKD, when cysts are still attached
to the parent tubule [60]. Cysts separate from the
tubule of origin when theyreach~200 mm indiameter
and continue to expand through a transepithelial
chloride secretion mechanism mediated by cAMP
[61]. Chloride enters cells via the basolateral Na-K-Cl
cotransporter and accumulates in the cytoplasm. A
chloride channel in the apical membrane, CFTR,
mediates movement of chloride into the cystic lumen.
Chloride secretion drives sodium into the cysticcavity
through paracellular mechanisms; this causes move-
ment of water through aguaporins [61]. In contrast to
ADPKD, cysts in ARPKD do not separate from
affected collecting ducts. Therefore, proliferation but
not transepithelial secretion is a major component
causing cystic kidney volume enlargement in
ARPKD.
Impaired cell-cell/matrix adhesion. The overlapping
expression and localization patterns of polycystin-1
and -2 support their role as a complex in regulating
multiple processes in tubular epithelia [62]. Both
proteins are found in basolateral membranes and the
primary cilium, where they may act together to
regulate cellular adhesion and Ca
2+ signaling. On the
other hand, polycystin-2 is mainly expressed in
endoplasmic reticulum, where it functions as a Ca
2+
releasechannel[45].Inaddition,polycystin-1ishighly
expressedduringdevelopment,withsignificantdown-
regulationofitsexpressioninadulttissues.Incontrast,
expression of polycystin-2 seems to persist into adult
life [62].
Experimental evidence from several groups has
established an important role for polycystins in
epithelial cell morphogenesis, including differentia-
tion and maturation in vivo [63, 64]. Studies using in
vitro models of tubulogenesis and cystogenesis based
on MDCK cells demonstrated that expression of
polycystin-1atcell-celljunctionsatcontrolledlevelsis
critical for proper tubular differentiation [65]. It has
been shown that polycystin-1 is directly involved in
intercellular adhesion via formation of strong homo-
philic interactions of its PKD (Ig-like) domains as
shown in Fig. 2 [36]. A direct role for Ig-like domains
in cell-cell adhesion was demonstrated by specific
perturbation of intercellular adhesion using antibod-
ies against Ig-like domains in cell cultures [36, 37].
Polycystin-1 was localized to the cell-cell adhesion
complexes with adherens junctions and desmosomal
junctionsinepithelialcellsofdifferentorigin[65–67].
Because alterations in polycystin-1-mediated adhe-
sionmaycausetheabnormalepithelialcellphenotype
observedinADPKDcells,includingdedifferentiation
and loss of epithelial polarity, several studies exam-
ined cell-cell adhesion junctions in primary cells
derived from ADPKD kidneys [37, 68, 69]. As
shown in Fig. 2, abnormal adherens and desmosomal
junctions were found in ADPKD: intracellular junc-
tions were devoid of desmosomal cadherins and
associated proteins, which were sequestered to the
cytoplasmic pools, and adherens junctions appeared
disrupted, accompanied by a great reduction of E-
cadherin expression and partial compensatory ex-
pression of N-cadherin [68].
Interestingly, co-immunoprecipitation studies in
ADPKD cells using an anti-polycystin-1 antibody
showed that E-cadherin was lost from the complex,
while beta-catenin remained associated with polycys-
tin-1.Moreover,beta-cateninwasstillexpressedatthe
plasma membrane despite the loss of E-cadherin,
suggesting the presence of an alternative cadherin
[68]. N-cadherin, but not K-cadherin, was overex-
pressed in ADPKD cells and formed a complex with
beta-catenin. In normal kidney, E-cadherin is ex-
pressed in distal segments of the nephron, while N-
cadherin is expressed in proximal tubules [70]. In the
ADPKD kidney, N-cadherin is markedly increased in
cysts of distal origin [68]. However, the expression of
N-cadherin in place of E-cadherin in ADPKD cells
was not sufficient to maintain epithelial cell-cell
adhesion [37, 69].
Polycystin-1 was shown to be indispensable in cell-
matrix interactions (Fig. 2) [54, 71]. Abnormalities in
the basement-membrane composition and expression
of matrix metalloproteases and their inhibitors were
identified in PKD kidneys. Interestingly, the inactiva-
tion of tensin and insertional mutation in laminin
alpha five result in cystogenesis [72, 73]. It has been
shown that polycystin-1 interacts with focal adhesion
complex molecules including a1b2 integrin, vinculin,
paxillin, p130-cas, talin and focal adhesion kinase
(FAK) [38]. In ADPKD cells, the focal adhesion
complex is disrupted due to loss of FAK (Fig. 2).
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numerous other proteins or cystoproteins such as
nephrocystin-1, -3, -4, -5, inversin, ALMS1, OFD1,
BBS1-8, cystin,polarisandNek8,whichcausePKDin
humans and animals, were recently discovered in a
distinct subcellular compartment, the primary cilium
[10, 74, 75]. Cilia are microtubule-containing organ-
elles that project from the surface of most eukaryotic
cells[76].Theprimary(non-motile)ciliaareknownto
transduce sensory stimuli such as concentrations of
growth factors, osmolarity and fluid flow [76]. They
primary cilia are formed in fully differentiated cells
during interphase and grow out of the basal bodies
(Fig. 3). The ciliary basal body is formed by the
centrosomes, more specifically by the mother cen-
triole that moves to the membrane where the axo-
neme,thestructuralcore,isformed[77].Construction
and maintenance of the axoneme requires a bidirec-
tional intraflagellar transport system (IFT) to deliver
structural components from the cell body to the tip of
the cilium.
It was recently discovered that defects in ciliary
structure or function underlie multiple human dis-
eases with diverse phenotypes, including retinal
degeneration, neural tube defects, obesity, polydacty-
ly and PKD. Initial linkage between cilia and PKD
came from mating behavior studies in Caenorhabditis
elegans [78]. Mutations in the lov-1 and PKD-2 genes
of C. elegans, which are closely related to human
polycystins, were associated with mechanosensation
defects of ciliated sensory neurons. Direct evidence
linkingdefectsinciliogenesisandPKDcamefromthe
study of renal tissue-specific inactivation of KIF3A, a
subunit of kinesin-II essential for cilia formation [79]:
Figure 2. Polycystin-1 in cell-cell/matrix adhesion in normal and ADPKD epithelia. (a) Polycystin-1 (PC-1) mediates cell-cell adhesion
through homophilic interactions of its Ig-like domains. It localizes with desmosomal junctions (DJs) and adherens junctions (AJs). The
components of DJs are shown: desmoplakin (Dp), desmogleins (Dsg), desmocollins (Dsc) and plakoglobin (Pg) [121]. AJs consist of E-
cadherin(E-cad)aswellasa,bandg-catenins(catenins).TheAJcomplexprovidesalinkagetotheactincytoskeleton,andDJlinktogether
intermediatefilaments(IF)ofepithelialcells. InADPKDepithelialcells,dysfunctionalPC-1(crossedredlines)anddesmosomal proteins
arelostfromcell-cellcontactsandremaininintracellularvesicles.Inaddition,E-cadherinexpressionisreduced,resultingincompensatory
expression of N-cadherin (N-cad). Thus, AJs and DJs are disrupted in ADPKD cells, while tight junctions (TJ) remain intact. (b)
Expression of PC-1 in cell-matrix focal adhesion contacts. In normal epithelial cells, PC-1 is found in a complex with talin (TAL), paxillin
(PAX),vinculin(VINC),focaladhesionkinase(FAK),c-src(SRC),p130-cas(CAS),nephrocystin(NPH1)andtensin(TEN).InADPKD
cells, expression of FAK is lost from the focal adhesion complex.
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resulted in development of PKD. Several studies have
shown that defects in ciliary assembly are associated
with PKD. It was demonstrated that the primary cilia
in the cystic kidney of mice with a mutation in the
Tg737 gene (homologous to the IFT gene of Chlamy-
domonas,IFT88)areshorterthannormal[80].Onthe
otherhand,theprimaryciliaofcysticepithelialcellsin
jckmicewerefoundtobesignificantly longerthanthe
cilia in wild-type mice [75]; this study suggested that
ciliary protein Nek8, which is mutated in the jck mice,
may play a role in control of ciliary length. Taken
together, these data established a link between ciliary
dysfunction and PKD.
Cilia and mechanosensation in PKD. A number of
studies support a role for the primary cilium as a
mechanosensorinkidneytubularepithelia.Praetorius
et al. reported that the primary cilia of renal epithelial
MDCK cells can serve as a flow sensor [81]. Bending
the cilium resulted in intracellular Ca
2+ influx fol-
lowed by calcium release from IP3-sensitive stores.
The calcium signal was spread as a wave through gap
junctions of cells [81]. The authors concluded that the
primary cilium in MDCK cells is mechanically sensi-
tive and responds to flow by increasing intracellular
calcium. A subsequent study demonstrated that poly-
cystins can serve as flow-sensitive ciliary mechano-
sensors in kidney epithelia [46]. More specifically,
ciliarypolycystin-1andpolycystin-2 functiontogether
with ryanodine receptors to mediate mechanotrans-
duction into the intracellular Ca
2+ signaling response
(Fig. 3). The influx of Ca
2+ across the plasma mem-
brane constitutes the initial response to mechanical
stimulation, and downstream signaling is mediated
through intracellular Ca
2+ release [46]. It is possible
that polycystin-1 functions as a sensor of ciliary
bending,whilepolycystin-2transducesthemechanical
signal into a calcium response. Changes in intra-
cellular Ca
2+ concentration are known to regulate
Figure 3. Ciliary functions of cystoproteins: mechanosensation and cell cycle control. Polycystin-1 (PC-1), polycystin-2 (PC-2) and other
cystoproteins(notshown)areexpressedinprimarycilia,basalbodiesorcentrosomes.Theprimaryciliumformsinfullydifferentiatedcells
in the G0 phase of the cell cycle. A cilium protrudes from the basal body (centrosome) formed by two centrioles, a mother centriole (blue
cylinder) and a daughter centriole (orange cylinder). As cells enter the cell cycle, the cilium is resorbed, and the centrosome can act as a
mitotic spindle pole organizer. Flow-induced bending of cilia in renal epithelial cells triggers Ca
2+ influx mediated by PC-2 in association
withPC-1.Theroleofciliaryproteinsincellcyclecontrolissupportedbyseveralfindings:(1)Inthenormalstate,PC-2sequestersId2[pro-
proliferative helix-loop-helix (HLH) protein] in the cytoplasm, preventing it from entering the nucleus. In PKD, when PC-1 or PC-2 are
inactivated, Id2 translocates to the nucleus and interacts with E-protein, blocking its ability to induce growth-suppressive genes and
resultinginincreasedactivityofcdk2andactivationofcellproliferation;(2)PC-1canactivatetheJAK/STATsignalingpathway,resulting
in the induction of p21
waf1 and cell cycle arrest in G0 and G1; (3) The intraflagellar transport component IFT88/polaris is capable of
controllingG1/Stransitionofthecellcycle.IFT88/polarisremainsassociatedwiththecentrosomethroughoutthecellcycle,whereitforms
a complex with Che-1, thus modulating its binding to Rb protein.
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cell cycle, differentiation and apoptosis. Cells with
mutated polycystin-1 fail to respond to the fluid flow:
it was shown that in ADPKD-derived cells, the ciliary
mechanosensation of fluid-flow shear stress by poly-
cystins is absent [46].
Cilia and cell cycle. There is an intimate link between
cilia and the cell cycle. The basal bodies/centrosomes
of the cilia act as organizers of the mitotic spindle
poles during cell division, directly connecting cilio-
genesis with cell cycle regulation, and cilia are
resorbed when cells enter the cell cycle (Fig. 3). As
we discussed previously, a number of cystoproteins
causing PKD in humans and animals are expressed, at
least partially, in cilia or the basal body of the cilia.
Polycystins and other cystoproteins may play an
important role in connecting the mechanosensory
function of the cilia to the centrosome and thus
influence cell cycle control. Disruption of cystopro-
teins associated with cilia or basal bodies could,
therefore, lead to dysregulation of the cell cycle and
proliferation, resulting in cystic disease.
Several lines of evidence support this hypothesis:
Overexpression of exogenous polycystin-1 in cultured
cells resulted in growth arrest in G0/G1 phase of the
cellcycle(Fig. 3)[82].Furtheranalysishasshown that
polycystin-1 expression inhibits Cdk2 and induces
p21
waf1. Polycystin-1 activates the JAK-STAT path-
way, thereby up-regulating p21waf1 and inducing cell
cycle arrest in G0/G1. Functional polycystin-2 was
shown to be essential for this process [82]. Other
cystoproteinslocalized tociliahavealsobeenrecently
shown to directly regulate the cell cycle. For example,
the IFT88/polaris protein, a component of the IFT,
was shown to be tightly associated with the centro-
some during cell cycle transitions [83]. Similar to
polycystin-1, overexpression of polaris resulted in cell
cycle arrest at the G0/G1 stage (Fig. 3). On the other
hand, down-regulation of polaris mRNA promoted
progression of the cell cycle. Polycystin-2 has been
shown to participate in cell cycle regulation as well: it
canassociatewiththehelix-loop-helixproteinId2and
block its translocation to the nucleus, preventing
proliferation [84]. The translocation of Id2 in cells
with mutated polycystins is associated with down-
regulation of p21 expression, leading to an increase in
CDK2 activity and cell cycle progression (Fig. 3).
Thus, evidence of a direct link between cystoproteins,
ciliary dysfunction and cell cycle dysregulation con-
tinues to accumulate.
Other signaling pathways affected in PKD
As we discussed previously, PKDs in humans and
animals canbe caused bydifferentcystogenesand can
be distinguished by the patterns of inheritance and
clinical manifestation. On the other hand, cyst for-
mation in these disorders is clearly characterized by
common features at the cellular and molecular levels.
Common cellular abnormalities of cystic epithelia
include increased proliferation, apoptosis, loss of
epithelial polarity accompanied by missorting of
proteins and intracystic fluid secretion. Ciliary dys-
function may also constitute one of the common
features for cystic diseases, since most known cysto-
proteins are associated with cilia/centrosome. Recent
evidencesuggeststhatcystoproteinsmayphysicallyor
genetically interact. For example, polycystin-2 was
found to directly interact with fibrocystin to regulate
calcium responses in the kidneys [53]. Genetic inter-
action between murine genes encoding polycystin-1
and fibrocystin was shown, suggesting that polycys-
tin-1 and fibrocystin function in the same molecular
pathway to maintain tubular integrity [85]. In addi-
tion, genetic interaction was also identified between
cystogenes encoding polycystin-1 and Nek8 (mutated
in the jck mouse model of PKD) (Natoli et al.,
unpublished observations). Therefore, elucidation of
common pathogenic mechanisms involved in PKDs is
an important step toward developing new therapies
for effective treatment of cystic diseases.
cAMP-activated pathways. Studies using in vitro-
cultured cells from ADPKD cysts and animal models
of PKD have revealed an important role for cAM-
P-activated pathways. cAMP was shown to block
proliferationofnormalkidneyepithelialcellsthrough
inhibitionoftheRas/Raf/MEK/ERKpathway[86].In
sharpcontrast,cAMPwasabletoinduceproliferation
of ADPKD-derived cystic epithelial cells through
activation of the B-Raf/MEK/ERK pathway. This
switchfromconventionalcAMP-inducedinhibitionof
growth to the cAMP-induced stimulation ofgrowth in
cystic epithelia was mediated by decreased intra-
cellular calcium levels [87]. Mutated polycystins
disrupted Ca
2+ signaling, which led to abnormal
cAMP-stimulated proliferation of cystic cells. Cystic
kidneys were shown to accumulate high levels of
cAMP inmultiplemodels ofPKD,makingitplausible
that activated cAMP pathways lead to both the
increased proliferation and fluid secretion seen in
cystic epithelia [86, 88, 89].
Wnt signaling in PKD. Activated Wnt signaling was
initially implicated in PKD through studies demon-
strating that overexpression of the cytoplasmic tail of
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stimulates TCF-dependent gene transcription in vitro
[90]. Microinjection of the polycystin-1 cytoplasmic
tail induced dorsalization in zebrafish, suggesting that
polycystin-1 is involved in modulating Wnt signaling
during renal development [90]. Other studies sup-
ported this finding by connecting dysregulation of the
beta-catenin pathway with PKD. Overexpression of
beta-catenin in transgenic animals or inactivation of
APC resulted in the development of cystic kidneys
[91, 92]. Canonical beta-catenin-dependent Wnt sig-
naling is required for kidney development, while
constitutive beta-catenin signaling in maturing tu-
bules leads to formation of cysts. Flow-induced
signaling switches the Wnt pathway to a non-canon-
ical beta-catenin-independent pathway through in-
creased expression of inversin, a protein mutated in
nephronophthisis type II [93]. This, in turn, results in
reduced levels of the cytoplasmic dishevelled protein
thatactivatesdestructionofthebeta-catenincomplex.
mTOR activation. The PKD1 gene is located in close
proximity to the TSC2 gene, which encodes the
tuberin protein responsible for the tuberous sclerosis
complex (TSC), in a tail-to-tail orientation. Patients
with contiguous PKD1-TSC2 gene syndrome develop
a severe PKD. These observations suggested that
polycystin-1 and tuberin may function in a common
molecular pathway. A functional link between poly-
cystin-1 and tuberin was established by a study
showing that tuberin is required for membrane
trafficking of polycystin-1 [94]. Polycystin-1 appeared
to form a complex with tuberin and regulate the
activity of mTOR, an important regulator of protein
synthesis and cellular differentiation [95]. The muta-
tions in polycystin-1 may therefore lead to persistent
activationofmTORinPKD.Infact,increasedmTOR
activity was identified in epithelial cells lining
ADPKD cysts. Activation of mTOR was also found
inanimalmodelsofrecessivePKDsuchasthebpkand
orpk-rescue, suggesting that mutations in polycystin-1
arenotcriticalformTORactivation.Itispossiblethat
signaling through other membrane receptors could
lead to stimulation of mTOR pathway, which is likely
to be a late stage of the cystogenesis cascade.
Therapeutic approaches for the treatment of PKD:
preclinical and clinical testing
Preclinical PKD animal models. Greater understand-
ingofthemolecularmechanismsofcystformationand
growth has led to the discovery of novel potential
therapeutictargets.AnimalmodelsofPKDhavebeen
critical in supporting studies of disease pathogenesis
and in testing potential therapies. The availability of
well-characterized and disease-relevant models is
instrumental for successful development of viable
therapies. Several preclinical PKD models have been
described, some with spontaneous mutations and
others generated through chemical/genetic manipu-
lations [96]. Mutations in these models occurred in
different genes, including Pkd1 and Pkd2. No existing
modelisidealforpreclinicaltestinginPKD;however,
each represents a facet of human pathobiology
(Table 1). In general, an ideal PKD model should
carry a mutation in a gene orthologous to the human
disease-carryinggene.Thedevelopmentofthedisease
in such orthologous models should reproduce human
PKD relative to the severity, segmental origin of
kidney cysts, extrarenal manifestations and known
cellular and molecular abnormalities including in-
creased proliferation, apoptosis, cAMP, protein mis-
sorting as well as activation of known signaling
pathways such as Wnt, b-Raf/MEK/ERK and mTOR.
Numerous attempts to produce such models have not
yet been successful. A dozen different mouse models
with targeted disruption of the Pkd1 gene have been
created, including animals with conditional gene
inactivation (reviewed in [96]). Mice with heterozy-
Table 1. Rodent models of polycystic kidney diseases used in therapeutic intervention studies.
Model Gene Protein Progression Renal pathology Kidney
phenotype
Mouse
cpk Cys1 Cystin Rapid PT, CD ARPKD
bpk Bicc1 Bicaudal C Rapid PT, CD ARPKD
orpk Tgn737 Polaris Rapid PT, CD ARPKD
pcy Nphp3 Nephrocystin-3 Slow nephron, CD ADPKD
jck Nek8 Nek8 Moderate LH, DT, CD ADPKD
Pkd1
-/- Pkd1 Polycystin-1 EL – ARPKD
Pkd2
-/ws25 Pkd2 Polycystin-2 Slow PT, LH, DT, CD ADPKD
Rat
Han:SPRD-cy Pkdr1 SamCystin Slow PT ADPKD
pck Pkhd1 Fibrocystin Slow CD ARPKD
PT, proximal tubule; DT, distal tubule; CD, collecting duct; LH, loop of Henle; EL, embryonic lethal.
612 O. Ibraghimov-Beskrovnaya and N. Bukanov Polycystic kidney diseasegous Pkd1 and Pkd2 mutations develop a very mild
and heterogeneous kidney cystic disease late in life
and therefore are not suitable for therapeutic testing.
Homozygous animals develop renal and pancreatic
cysts at embryonic day 15.5 and die during embryo-
genesis. Mice with conditional inactivation of the
Pkd1 gene develop kidney and liver cysts, but disease
istoomildtobeinformativeinpreclinicaltesting[97].
An interesting mouse model with a mutation in the
Pkd2 gene (Pkd2
–/WS25) carrying an unstable allele
combined with a Pkd2-null allele has been described
[98].Althoughtheseanimalsdevelopkidneyandliver
cystic disease that mimics human ADPKD, the model
hasnotbeenwidelyusedfortherapeutictestingdueto
a very high degree of phenotypic heterogeneity in
combinationwithaslowcourseofprogressionwithno
measurable loss of renal function as late as 4–
6 months of age. The Pkd2
–/WS25 model should be
most useful as a secondary confirmatory model rather
than the primary model for proof of concept ther-
apeutic testing [96]. Several spontaneous mouse
models of PKD, such as cpk, bpk and orpk, resemble
human recessive disease with respect to cyst local-
ization and the rapid rate of disease progression
(Table 1). Cystic disease in the pcy mouse and
Han:SPRD rat is slowly progressive with cyst forma-
tion similar to ADPKD. The jck mouse model is
characterized by the development of cysts in multiple
nephron segments and, despite the autosomal reces-
sive mode of inheritance, resembles human ADPKD
phenotypically and can be used for relatively rapid
therapeutic testing [75]. Since no single model fully
recapitulates all aspects of human PKD pathogenesis,
it is important to test a potential therapy in more than
one PKD model to determine its utility for clinical
testing.
EGF receptor tyrosine kinase inhibitors. An impor-
tant role for epidermal growth factor (EGF) and its
receptor (EGFR) in contributing to cystic epithelial
proliferation has been demonstrated. In human PKD
and multiple animal models, EGFR is overexpressed
and mislocalized to the apical membrane in cystic
epithelial cells [57].Transforming growth factor alpha
(TGF alpha), a member of EGF family, also signals
throughEGFR.TheroleofTGFalphaincystogenesis
was addressed by renal expression of a TGF alpha
transgene in the mouse [58]. Overexpression of TGF
alpha in transgenic animals resulted in formation of
renal cysts. Preclinical studies showed that inhibition
ofEGFRtyrosinekinaseactivitysignificantlyreduced
cystogenesis in mouse models of PKD, including bpk
and orpk, as well as in the Han:SPRD rat model [99,
100], all models characterized by overexpression and
mislocalization of EGFR to the apical membrane.
However, no therapeutic effect was detected in the
PCK rat; interestingly, although the PCK rat is an
orthologous model of ARPKD, EGFR was not found
tobemislocatedtotheapicalmembraneofcysticcells,
which may explain the lack of therapeutic efficacy in
this model [101].
Inhibition of apoptosis. Cystogenesis is characterized
by enhanced apoptosis. Growth of cysts in 3-D
collagen cultures of epithelial cells in vitro proceeds
with increased apoptosis [102]. Moreover, deletion of
theanti-apoptoticBcl-2andAP-2betagenesaswellas
overexpression of pro-apoptotic c-myc in mice leads
to renal cyst formation [103, 104]. To test the effect of
inhibitionofapoptosisinPKD,acaspaseinhibitorwas
tested in the Han:SPRD rat model [105]. This study
showed inhibition of PKD progression and attenua-
tion of the loss of renal function.
Modulation of cAMP signaling. Multiple studies have
showntheimportanceofcAMP-activatedpathwaysin
PKD. The critical role of the cAMP-activated B-Raf/
MEK/ERK pathway was confirmed by the successful
preclinical testing of a MEK inhibitor [106]: oral
administration the MAP/ERK kinase inhibitor
PD184352 to pcy mice significantly decreased kidney
weight, serum creatinine levels and water intake and
significantly increased urine osmolality. Thus, inhib-
itors of the B-Raf/MEK/ERK pathway may prove to
be promising agents for PKD therapy.
Studies were conducted to specifically target the
cystogenic cAMP and vasopressin pathways using
vasopressin V2 receptor (VPV2R) inhibitors, and
efficacy was shown in four different PKD animal
models [107]. Treatment with Tolvaptan (human
VPV2R antagonist, Otsuka Pharmaceutical) resulted
in significant lowering of cAMP levels in PCK rat
kidneys and inhibition of renal cystogenesis and
fibrosis. Tolvaptan has entered human clinical trials
in ADPKD, and phase II results have shown that it is
well tolerated, with thirst and polyuria as side effects
[88, 108]. It is important to note that effective
reduction of plasma vasopressin levels through in-
creased water intake decreased VPV2R expression
and slowed PKD progression in PCK rats [109].
As somatostatin is capable of inhibiting cAMP-stimu-
lated fluid secretion, it constitutes an alternative ap-
proach to the targeting of abnormal cAMP signaling in
cysts. In a randomized placebo-controlled human
ADPKD trial, the benefit of a 6-month treatment with
long-acting somatostatin (octreotide-LAR, 40 mg intra-
muscularly every 28 days) was assessed [110]. This study
indicated that somatostatin therapy is safe and may slow
disease progression. Several clinical trials with somatos-
tatin are now being implemented.
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rescue mouse models with the mTOR inhibitor
rapamycin showed effective inhibition of PKD [95].
This effect was mediated by selective induction of
apoptosis in cystic cells. Similar results were previ-
ously observed in a separate study with rapamycin
performed in Han:SPRD rats [111]. Treatment of
human ADPKD transplant recipient patients with
rapamycin resulted in a significant reduction in
polycystic kidney volumes [95]. Several clinical trials
are currently underway to test the efficacy of rapa-
mycin and everolimus in ADPKD patients.
Cyclin-dependent kinase (CDK) inhibition. An im-
portantroleofciliarydysfunctioninPKDpathologyis
highlighted by findings of the disrupted connection
between cilia and the cell cycle. This dysregulation
betweenciliaandcellcycleprogressionseemstooccur
early in cystogenesis and represents an attractive
therapeutictarget.TheCDKinhibitorroscovitinewas
tested in cystic assay in vitro and in the preclinical
PKD mouse models jck and cpk [89]. Roscovitine
(Seliciclib, CYC202) is a potent and remarkably
selective inhibitor of CDK2/cyclin E, CDK7/cyclin
H, CDK9/cyclin T1 and CDK5/p35-p25 [112, 113].
Robust inhibition of PKD was shown in the jckmouse
model of slowly progressive disease as well as in the
cpk mouse model of aggressive PKD. Pulse treatment
resulted in a persistent long-lasting effect such that
continuous daily administration of the drug was not
required to achieve efficacy. Roscovitine was equally
effective against cysts formed in different segments of
the nephron, a desirable feature for a potential drug
against ADPKD, where cysts are formed in multiple
parts of the nephron. The effect of roscovitine at the
molecular level was mediated through cell cycle
blockade, transcriptional inhibition and apoptotic
arrest [89]. Thus, the apparent therapeutic benefit of
CDK inhibition for PKD may be due to integrative
effects on several key aspects of disease pathology.
Seliciclib, an orally bioavailable compound, is cur-
rently in clinical trials as a cancer drug candidate
[114]. Preliminary clinical testing showed that Selici-
clib can be administered safely without major side
effects. Known adverse events include transient
elevations in serum creatinine, transient hypokalemia
and reversible elevations in liver enzymes [114].
Stimulation of polycystin-2-mediated Ca
2+ release.
The deregulation of Ca
2+ signaling in cystic cells is
believed to be mediated by polycystin-2 in complex
with polycystin-1. The first example of a therapeutic
strategy to promote an increase in cytosolic Ca
2+ in
PKD has been demonstrated by treatment with
triptolide, an active diterpene used in traditional
Chinesemedicine[115].TriptolidetreatmentofPkd1-
null homozygous embryos via maternal administra-
tion of the drug resulted in arrest of cellular prolifer-
ation and inhibition of cyst formation through resto-
ration of Ca
2+ signaling.
Integrated approach for drug discovery. The majority
– if not all – of the drugs successfully tested in animal
models so far were not specifically designed to treat
PKD but rather were originally developed for other
indications. Some of these drugs may require further
optimization to achieve efficacy/toxicity profiles that
aremoreappropriateforthePKDpatientpopulation.
Because multiple optimized analogues would need to
be tested, direct assessment of their efficacy in animal
models is not feasible. The availability of high-
throughput in vitro screening assays that are disease-
relevant, robust, rapid and reproducible is crucial. In
addition,suchassayscanbedirectlyusedfordiscovery
of PKD-specific compounds that antagonize cyst
development. It has been shown that MDCK cysts
grown in a 3-D collagen matrix in vitro adequately
reflect several aspects of cystogenesis in vivo and can
be successfully used for drug testing (Fig. 4) [65, 116,
117]; the cystic assay can be used directly for high-
throughput screening of a compound library or as a
drugoptimizationassay.Recentlyitwasshownthatan
embryonic cystic kidney organ culture assay can be a
very valuable testing platform for rapid assessment of
efficacy as well as preliminary testing for organ
toxicity before entering into time- and material-
consuming trials in animals ([118] and T. Natoli,
unpublished results) (Fig. 4). With the availability of
such a screening cascade and successful candidates
already emerging from preclinical testing, the field is
poised to suggest viable therapeutic options for the
treatment of PKD.
Assessment of therapeutic efficacy in clinical trials.
Several potential therapies, including tolvaptan,
sirolimus, everolimus and octreotide (as discussed
above), are being tested in ongoing ADPKD clinical
trials. In addition, a large clinical trial (HALT-PKD)
has been implemented to address the benefit of
inhibition of the renin-angiotensin system [119]; this
trial will test whether using ACE inhibitors and
angiotensin receptor blockers in combination is
beneficial in comparison with ACE inhibitors
alone. The main challenge in ADPKD clinical trials
is the primary outcome measure. Because disease
develops slowly over several decades, renal function
begins to decline late in the course of the disease
when significant and likely irreversible damage to
thekidneyoccurs.Morebeneficialearlyintervention
trials require availability of reliable endpoints pre-
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Results of the CRISP (Consortium for Radiologic
Imaging Studies of PKD) study have demonstrated
that measurement of kidney volume by magnetic
resonance imaging (MRI) can be a reliable indicator
of clinical outcome [120].
Conclusions
Recentadvancesinourfundamentalunderstandingof
the molecular pathogenesis of PKD have allowed
selection of disease-relevant targets for therapeutic
testing. Several successful studies in animal models
that are currently being translated into human clinical
trials strengthen the need to further explore disease-
specific therapeutic targets. A rapidly growing num-
berofwell-characterizedinvitroandinvivomodelsof
cystic disease open opportunities for systematic drug
discovery efforts. The availability of magnetic reso-
nance imaging techniques to accurately measure PKD
progressionand,subsequently,theeffectoftherapeutic
agents in a short period of time greatly enhances
options for clinical trial design. It is likely that future
treatment for PKD will require a combination therapy
integrating several key pathways of cystogenesis. The
futureofthetreatmentoptionsforPKDisabrightone.
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